D
David E. Newby
Researcher at University of Edinburgh
Publications - 902
Citations - 45577
David E. Newby is an academic researcher from University of Edinburgh. The author has contributed to research in topics: Myocardial infarction & Coronary artery disease. The author has an hindex of 98, co-authored 805 publications receiving 35865 citations. Previous affiliations of David E. Newby include NHS Lothian & Queen's University.
Papers
More filters
Journal ArticleDOI
Endothelin antagonism in pulmonary hypertension, heart failure, and beyond
TL;DR: This review will review the evidence for the two therapeutic areas mainly investigated, pulmonary arterial hypertension and heart failure, as well as outline its important role in hypertension, renal dysfunction, and atherosclerosis.
Journal ArticleDOI
Randomised controlled trial of continuous positive airway pressure and standard oxygen therapy in acute pulmonary oedema; effects on plasma brain natriuretic peptide concentrations.
C. A. Kelly,David E. Newby,Theresa McDonagh,T. W. Mackay,Jordi Barr,N A Boon,H. J. Dargie,Neil J. Douglas +7 more
TL;DR: CPAP produces a more rapid clinical and symptomatic improvement in patients with acute pulmonary oedema, particularly within the first hour, suggesting CPAP is a useful adjunctive treatment in the early management of acute heart failure.
Journal ArticleDOI
Non-invasive measures of pulse wave velocity correlate with coronary arterial plaque load in humans.
Andrew L McLeod,Neal G. Uren,Ian B. Wilkinson,David J. Webb,Simon Maxwell,D B Northridge,David E. Newby +6 more
TL;DR: Findings are consistent with the suggestion that central aortic stiffness may promote the development of coronary atherosclerosis and ischaemic heart disease and may be a useful non-invasive surrogate marker for the extent of coronary Atherosclerosis.
Journal ArticleDOI
Diagnosis of obstructive coronary artery disease using computed tomography angiography in patients with stable chest pain depending on clinical probability and in clinically important subgroups: Meta-analysis of individual patient data
Robert Haase,Peter Schlattmann,Pascal Gueret,Daniele Andreini,Gianluca Pontone,Hatem Alkadhi,Jörg Hausleiter,Mario J. Garcia,Sebastian Leschka,Willem B. Meijboom,Elke Zimmermann,Bernhard Gerber,U. Joseph Schoepf,Abbas Arjmand Shabestari,Bjarne L. Nørgaard,Matthijs F.L. Meijs,Akira Sato,Kristian A. Øvrehus,Axel Cosmus Pyndt Diederichsen,Shona M.M. Jenkins,Juhani Knuuti,Ashraf Hamdan,Bjørn Arild Halvorsen,Vladimir Mendoza-Rodriguez,Carlos E. Rochitte,Johannes Rixe,Yung-Liang Wan,Christoph Langer,Nuno Bettencourt,Eugenio Martuscelli,Said Ghostine,Ronny R. Buechel,Konstantin Nikolaou,Hans Mickley,Lin Yang,Zhaqoi Zhang,Marcus Y. Chen,David A. Halon,Matthias Rief,Kai Sun,Beatrice Hirt-Moch,Hiroyuki Niinuma,Roy P. Marcus,Simone Muraglia,Reda Jakamy,Benjamin J.W. Chow,Philipp A. Kaufmann,Jean-Claude Tardif,Cesar Nomura,Klaus F. Kofoed,Jean Pierre Laissy,Armin Arbab-Zadeh,Kakuya Kitagawa,Roger J. Laham,Masahiro Jinzaki,John Hoe,Frank J. Rybicki,Arthur J. Scholte,Narinder Paul,Swee Yaw Tan,Kunihiro Yoshioka,Robert Röhle,Georg M. Schuetz,Sabine Schueler,Maria H. Coenen,Viktoria Wieske,Stephan Achenbach,Matthew J. Budoff,Michael Laule,David E. Newby,Marc Dewey +70 more
TL;DR: In a no-treat/treat threshold model, the diagnosis of obstructive CAD using coronary CTA in patients with stable chest pain was most accurate when the clinical pretest probability was between 7% and 67%.
Journal ArticleDOI
Multicenter Safety and Practice for Off-Label Diagnostic Use of Ferumoxytol in MRI.
Kim-Lien Nguyen,Takegawa Yoshida,Nikhita Kathuria-Prakash,Islam H Zaki,Csanad Varallyay,Scott Semple,Rola Saouaf,Cynthia K. Rigsby,Cynthia K. Rigsby,Sokratis Stoumpos,Kevin K. Whitehead,Lindsay M. Griffin,Lindsay M. Griffin,Lindsay M. Griffin,David Saloner,Michael D. Hope,Martin R. Prince,Mark A. Fogel,Mark L. Schiebler,Giles Roditi,Aleksandra Radjenovic,David E. Newby,Edward A. Neuwelt,Mustafa R. Bashir,Peng Hu,J. Paul Finn +25 more
TL;DR: Diagnostic ferumoxytol use was well tolerated, associated with no serious adverse events, and implicated in few adverse reactions, and Registry results indicate a positive safety profile for ferum oxytolUse in MRI.